MEPSGEN Signs Research Agreement with KAIST Team to Develop Retinal Vascular Barrier Model
2025-05-15
[Interview] MEPSGEN's CEO warns of overlooked RNA damage risk during LNP manufacturing
2025-05-02
MEPSGEN Presents Advanced Nanoparticle Technology at LNP Summit in Boston
2025-04-17
MEPSGEN Unveils 'NanoCalibur GMP' for Preclinical and Clinical Nanoparticle Production
2025-03-13
MEPSGEN Collaborates with University of Utah for Corneal Model Research
2025-03-05
MEPSGEN and AIGEN Science Sign MOU to Advance Innovative Drug Development
2025-02-07
MEPSGEN appoints renowned MPS expert as new Chief Scientific Officer
2025-01-22
MEPSGEN CEO YongTae Kim says organ-on-chips will change the clinical paradigm by overcoming the limitations of animal testing.
2025-01-08
Mepsgen raises $14.9 million in series C funding, expands global reach
2024-11-19
NanoCalibur™ to Lead Innovation in Nanomedicine, CEO YongTae Kim Says
2024-10-24
Mepsgen launches automated nanoparticle production equipment ‘NanoCalibur’
2024-10-22
MEPSGEN Receives ￦5.6 Billion Research Grant from MOTIE
2024-08-06
Modeling of Human Organ Tissue Barrier on Organ-on-a-Chip
2024-07-22
MEPSGEN showcases ProMEPS, NanoCalibur at BIO International Convention 2024
2024-06-03
MEPSGEN showcases ProMEPS™ at BIO KOREA 2024
2024-05-02
MEPSGEN Attends 2024 HANKYUNG BIO INSIGHT FORUM
2024-03-11
MEPSGEN Attends 2024 JPMHC
2024-01-12
MEPSGEN Launched ProMEPS _ Automated MPS Modeling System
2023-12-07
MEPSGEN received Commendation from Minister of TIE
MEPSGEN unveils the world's first "Automatic Incubator" for MPS
2023-11-27
